New combo therapy aims to slow ovarian cancer progression
Disease control
Recruiting now
This study tests whether adding bevacizumab to niraparib after standard chemotherapy helps people with newly diagnosed advanced ovarian cancer live longer without the disease getting worse. About 970 participants will receive either niraparib alone or niraparib plus bevacizumab. …
Phase: PHASE3 • Sponsor: AGO Study Group • Aim: Disease control
Last updated May 02, 2026 06:04 UTC